Answers are grounded in this paper and cite their sources.
Protein kinase C (PKC) is a family of closely related phospholipid-dependent protein kinases. A fully active, phospholipid-independent catalytic fragment of PKC is produced by limited proteolysis of the enzyme. The catalytic fragment allows a simplified assay system for the analysis of PKC inhibitors that interact with the catalytic domain. Recently, we reported that N-myristoylation of the synthetic peptide substrate Arg-Lys-Arg-Thr-Leu-Arg-Arg-Leu (RKRTLRRL) transformed a peptide that completely lacked inhibitory activity against the histone kinase reactions of PKC and its catalytic fragment into a peptide that potently inhibited both of these reactions. N-Myristoylation did not alter the potency of the peptide as a PKC substrate, and the basis for the acquisition of inhibitory activity against the catalytic fragment by N-myristoylation of the peptide remained unclear. In this report, we propose a mechanism for catalytic fragment inhibition by the N-myristoylated peptide that is based on a comparison of the inhibitory potencies of several nonphosphorylatable analogs of N-myristoyl-RKRTLRRL, a kinetic analysis of the inhibition of the histone kinase activity of the catalytic fragment by nonphosphorylatable N-myristoyl-RKRTLRRL analogs, and an analysis of the inhibitory effects of the N-myristoylated peptide series on the intrinsic ATPase activity of PKC. Our results support a mechanism in which the N-myristoylated peptides inhibit the catalytic fragment by binding to PKCfree, but not to the complex PKC-ATP, at the protein-substrate binding site.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Ward et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: